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Abstract: Acute myocardial infarction (AMI) is the leading cause of death 
among cardiovascular diseases. Among the numerous attempts to develop 
coronary marker concepts into clinical strategies, cardiac troponin is known as 
a specific marker for coronary events. The cardiac troponin concentration 
level in blood has been shown to rise rapidly for 4–10 days after onset of AMI, 
making it an attractive approach for a long diagnosis window for detection. 
The extremely low clinical sensing range of cardiac troponin levels 
consequently makes the methods of detection highly sensitive. In this review, 
by taking into consideration optical methods applied for cardiac troponin 
detection, we discuss the most commonly used methods of optical 
immunosensing and provide an overview of the various diagnostic cardiac 
troponin immunosensors that have been employed for determination of 
cardiac troponin over the last several years. 
Biosensors are designed to detect target molecules in medical 
diagnostic procedures.1,2,3 In principle, they are generally fabricated by 
immobilizing the biological elements of, for instance, antibody, DNA or 
RNA, and enzyme on the surface of a transducer to convert the 
interaction between biological elements and target molecules into 
quantifiable signals.4,5,6,7,8 Due to the high affinity of antibodies to their 
target molecules, antibody and antigen binding are supposed to be 
practical methods for detecting specified biomarkers in human 
samples.9 Cardiovascular biosensors are classified as an extremely 
important and crucial diagnosing system not only for patient survival 
but also for reduction in cost and a great deal of time in successful 
prognosis of the disease. Acute myocardial infarction (AMI)1 has 
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remained a leading cause of morbidity and mortality worldwide.10 
Among many biomarkers, the earliest biomarkers for the detection of 
myocardial ischemia included aspartate aminotransferase, total lactate 
dehydrogenase, and lactate dehydrogenase isoenzymes.11 Another 
cardiac biomarker, creatine kinase (CK), is a cytosolic carrier protein 
for high-energy phosphates.12 
Creatine kinase MB (CK-MB) is an isoenzyme of creatine kinase 
that is most abundant in the heart. CK-MB is present in a small 
fraction of other organs such as the small bowel, uterus, prostate, and 
diaphragm.13 Therefore, the specificity of CK-MB can be reduced. 
Specificity comparison between CK-MB and other cardiac biomarkers, 
including troponin, showed that troponin (I or T) has been determined 
to have nearly absolute myocardial tissue specificity for myocardial 
damage and has high clinical sensitivity for myocardial ischemia.14,15 
Troponin is known as a complex of three regulatory proteins—troponin 
C, troponin I, and troponin T—that are related to skeletal and cardiac 
muscle contractions. Troponin complex form can perform as a receptor 
of calcium ions to induce structural changes through actin and myosin 
providing contraction.16,17 The troponin complex has three subunits: 
troponin C, which binds calcium; troponin I, which inhibits actin–
myosin interactions; and troponin T, which attaches the troponin 
complex by binding to tropomyosin and facilitates contraction. 
Troponin C is expressed by cells in both cardiac and skeletal muscle. In 
contrast, the amino acid sequences of troponins I and T are unique to 
cardiac muscle.18 
Cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are 
biomarkers for AMI diagnosis. Cardiac troponins (cTns) have been 
recommended for predicting and treating cardiovascular disease, 
especially AMI, because of their high sensitivity and specificity. cTnI is 
known as a specific marker for coronary events.19 Cardiac troponins as 
regulatory proteins control the calcium-mediated interaction of actin 
and myosin, which results in contraction and relaxation of striated 
muscle. Serum troponin levels in patients who are free of heart 
disease are very low or undetectable. After AMI symptoms, the level of 
troponin increases in 24 h and could increase up to 14 days after acute 
myocardial infarction.20 Following the myocardial damage, the troponin 
complex is broken up and the individual protein components are 
released into the bloodstream. Detection of cTnI and cTnT in 
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peripheral blood indicates cardiomyocyte damage. Because AMI is the 
most important cause of cell damage, both intracellular located cTns 
have become an integral part in the diagnosis of AMI. For this 
indication, determinations of cTn concentration and release kinetics 
are superior to all other biomarkers. Therefore, cTnI and cTnT are the 
preferred markers for the diagnosis of AMI. However, cTn indicates 
and provides an estimate of cardiomyocyte damage irrespective of its 
cause. Therefore, differential diagnoses of elevated cTns are to be 
considered. Electrocardiography (ECG) and cTn form the diagnostic 
cornerstones and complement clinical assessment for patients with 
acute chest pain, angina pectoris, or other symptoms suggestive of 
acute myocardial infarction. The troponin I clinical sensing ranges are 
extremely low, and the methods for detection are required to be highly 
sensitive.21,22,23,24 Therefore, the diagnostic sensitivity of troponin 
compared with other tests would be extremely high. 
Electrocardiography and cardiac troponin form the diagnostic 
cornerstones and complement clinical assessment for patients with 
acute chest pain, angina pectoris, or other symptoms suggestive of 
acute myocardial infarction. 
In this review, we summarize major advances and 
developments of optical biosensor technologies for detection of cardiac 
troponin I in biological fluids. To achieve the increasing demand of 
quick troponin diagnosis and consequently the clinical therapeutics, a 
plethora of methods have been used for detection of the troponin 
family, including enzyme-linked immunosorbent assay (ELISA),25 
chemiluminescent immunoassay,26 fluoroimmunoassay,27 electrical 
detection,28 surface plasmon resonance (SPR) detection,29 and 
colorimetric protein array.30 These optical biosensors for cardiac 
troponin detection, in comparison with electrochemical biosensors for 
troponin detection, are more bulky and expensive and also require 
difficult labeling procedures. For instance, colorimetric, fluorescence, 
and luminometric types of sensors involve difficult labeling procedures 
based on indirect indicator signal schemes. The significant merits of 
optical biosensors are high sensitivity and rapid antigen detection. 
It is worthwhile to consider the challenges in cardiac troponin 
detection biosensors such as improving sensitivity and specificity, low 
cost, low power, ease of miniaturization, and point-of-care 
capability.31,32 
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Optical biosensors 
In optical biosensors, the transducing structure is the critical 
part and different transducers can be used for generating an optical 
change, including grating couplers,33 resonant mirror,34,35 surface 
plasmon resonance (SPR),36 interferometry,37 reflectrometric 
interference spectroscopy,38 ellipsometry,39 and total internal reflection 
fluorescence (TIRF).40 
The SPR technique is based on measuring the refractive index of 
very thin layers of material adsorbed on a metal. In SPR 
immunosensing, the antibodies have been immobilized on the surface 
of a thin metal film, such as gold, deposited on the reflecting surface 
of a glass prism. When interactions between the antigens and 
immobilized antibodies occur, a change in the refractive index as 
variation in light intensity reflecting from the back of the film will be 
detected.41,42,43 
Localized surface plasmon resonance (LSPR) is a powerful 
technique for chemical and biological detection. LSPR is generated by 
light when it interacts with conductive nanoparticles (NPs) that are 
smaller than the incident wavelength. In LSPR, by incidence of light to 
the NPs, the electric field is deposited to collectively excite electrons of 
a conduction band, and the result is coherent localized plasmon 
oscillations with a resonant frequency and is affected by the 
composition, size, geometry, dielectric environment, and separation 
distance of NPs.44 
The generation of a guided mode in the SPR planar substrate 
improves the performance of SPR sensors. Plasmon waveguide 
resonance is based on the deposition of a dielectric layer over a gold 
or silver film. For this purpose, many conductive or dielectric materials 
have been used, including silica and titanium dioxides. Guided modes 
are highly sensitive to changes in the refractive index with both 
polarizations.45,46 Fig. 1 shows a schematic of the plasmon waveguide 
resonance biosensor.45 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Analytical Biochemistry, Vol 485 (September 15, 2015): pg. 1-10. DOI. This article is © Elsevier and permission has been 
granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
6 
 
 
Fig.1. Schematic showing the plasmon waveguide resonance biosensor.45 
Various integrated optical SPR sensors using slab waveguides, 
channel waveguides, and even more waveguide structures have been 
developed. Fig. 2 shows a schematic SPR method in an optical 
biosensor.47 
 
Fig.2. Schematic showing the SPR method in optical biosensor.47 
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Optical biosensors are based on the alteration in the phase, 
polarization, or frequency of the input light that is related to 
biorecognition processes. Optical biosensors are classified into different 
categories such as colorimetric, fluorescence, luminescence and 
surface plasmon resonance.32 In biosensors based on colorimetric or 
fluorescence detection, the target or biological elements are labeled 
with fluorescent tags or dyes.32 The presence of target molecules is 
determined when the change in intensity of fluorescence or color 
signal occurs. Colorimetric measurement is directly visible and 
convenient, whereas the sensitivity is much lower. In general, 
biosensors based on these methods have shown effective 
performance, but the demerits are sensitivity, miniaturization, and 
cost efficiency. SPR can be used to detect interaction between 
biological elements that are immobilized on the metal surface and its 
biospecific target.48 SPR immunosensors have been proposed for 
sensitive and quick detection of human troponin. Recently, biosensors 
based on luminescence methods have been developed for cardiac 
biomarker detection49,50 and have been categorized into two types, 
namely chemiluminescence and electroluminescence. 
The limit of detection is known as the lowest concentration of 
troponin that can be reliably differentiated. In addition, assays that 
have a lower limit of detection are considered more sensitive but not 
necessarily more precise. The limit of quantification is the lowest 
concentration that can be reliably detected and can produce an 
acceptable precision, and consequently the limit of quantification may 
be equivalent to the limit of detection or can be at a much higher 
concentration.51 The limit of quantification for troponin assay is the 
concentration with a total imprecision (coefficient of variation, CV) of 
10%. The importance of cardiac-specific troponin is that even small 
amounts of cardiac-specific troponin play a critical role in reflecting 
incremental risk and indicating myocardial injury.52 
Fluorescence-based biosensors for cardiac 
troponin detection 
Several immunoassay techniques may be used to monitor cTnI. 
Fluorescence-based biosensors have been developed to detect 
troponin I as well. For troponin I detection, fluoro-microbead guiding 
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chip (FMGC) performing by an optical immunoassay has been 
reported.53 
In 2011, Song and coworkers developed an optical 
immunoassay for cTnI. Antibody-tagged fluoro-microbeads were used 
to perform a sandwich immunoassay. The target antigen cTnI was 
added to cTnI capture antibody immobilized on the DTSP (3,3′-
dithiobis-propionic acid N-hydroxysuccinimide ester)-functionalized 
surface and then antigen antibody bound. Biotin-conjugated cTnI 
detection antibody was loaded into the chip and reacted for 30 min. 
Immobilized cTnI bound to fluoro-microbead-conjugated antibody. The 
microchannel was washed with phosphate-buffered saline (PBS), and 
then avidin-conjugated fluoro-microbeads were injected. The bound 
fluoro-microbead conjugates were measured directly using a 
conventional fluorescence microscope. Fig. 3 shows the design and 
schematic diagram of the sandwich assay on fluoro-microbeads 
guiding chip.53 
 
Fig.3. (A) Design of the fluoro-microbead guiding chip (FMGC). (B) Photograph of the 
FMGC. (C) Schematic diagram of the sandwich immunoassay using antigen–antibody 
binding (system 1) and avidin–biotin affinity binding (system 2) on the FMGC. The 
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avidin–biotin couple was used to enhance the signal.53 DTSP, 3,3′-dithiobis-propionic 
acid N-hydroxysuccinimide ester; SAM, self-assembled monolayer. 
Luminescence and colorimetric methods for cardiac 
troponin detection 
Because of the need for fast diagnosis for clinical therapeutics, 
biosensors have been designed to have small size and weight, fast 
response time, high sensitivity, and (importantly) ease of operation 
and fabrication.54,55 For colorimetry assay, materials such as silicon 
chips,56 glass surfaces,57 and gold electrodes58 have been developed. 
In 2010, Wu and coworkers proposed a biosensor based on the 
colorimetric method for cardiac troponin I detection. They showed that 
poly(dimethyl siloxane) (PDMS)–gold nanoparticles (AuNPs) composite 
film as a basis with silver enhancement can be employed by the 
colorimetric method for detection of cTnI.59 PDMS has merits such as 
excellent transparency, outstanding elasticity, good thermal and 
oxidative stability, ease of fabrication, and the ability to be sealed with 
various materials. Gold nanoparticles can be functionalized as an idle 
substrate with antigen, enzyme, and other biomolecules. Hence, 
applying AuNPs patterned on PDMS films has a great advantage in 
biosensor applications. AuNPs aggregate in a liquid system; therefore, 
AuNPs are first immobilized onto PDMS film and then covered with 
antibodies. After blocking the surface with bovine serum albumin 
(BSA) and capturing cTnI, silver enhancement solution is dropped onto 
the surface of the sensor and live photos are taken. AuNPs play the 
role of catalyst during reactions of silver reduction, and when protein 
covers the surface of NPs, the catalytic property of AuNPs could be 
wasted. Differences in the type, quality, and quantity of proteins that 
cover the surface of AuNPs influence the amount of reduction in silver 
metal and cause the color differences of the reaction mixture. The 
detection of cTnI using PDMS–AuNPs composite film is practically used 
for clinical diagnosis. The experimental procedure and a schematic 
diagram of silver enhancement colorimetric detection of cardiac 
troponin I are shown in Fig. 4.59 
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Fig.4. Experimental procedure for silver enhancement colorimetric detection of cardiac 
troponin I: (A) PDMS chip with HAuCl4 solution; (B) photo of PDMS–AuNPs composite 
film; (C) schematic diagram for colorimetric detection.59 
Chemiluminescence (CL) and electrochemiluminescence (ECL) 
biosensing platforms have been assessed for cardiac marker 
detection.60,61 A novel nanoparticle based on an ECL immunosensor 
has been employed for sensitive detection of human cTnI.22,62 The 
production of luminescence during electrochemical reaction is 
considered electrochemiluminescence. A high-sensitivity, wide-linear, 
low-background, and simple instrument that can be used for detecting 
the acute myocardial infarction biomarkers are taken into account as 
the positive characteristics of ECL. The unique property of 
nanoparticles in coupling with biomolecules is an important issue for 
developing biological nanoprobes.63 AuNPs have been functionalized by 
protein via electrostatic and other physical adsorption mechanisms, 
and due to the high surface-to-volume ratio of AuNPs, biomolecules 
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can be immobilized to the surface of them. Gold nanoparticles were 
functionalized by using N-(aminobutyl)-N-(ethylisoluminol) (ABEI)–
AuNPs and are used as labels via the simple seed growth method for 
ultrasensitive detection of cTnI in clinical diagnosis.62 Two kinds of 
nanoparticles, SA–AuNPs (streptavidin-coated gold nanoparticles) and 
ABEI–AuNPs–Ab2 nanoprobes, were used for the ECL immunosensor. 
SA–AuNPs enhance the conductivity or electron transfer between 
biomolecules and electrode and also improve immobilized capacity. 
There are two advantages to applying AuNPs in ABEI–AuNPs–Ab2 
nanoprobes. First, AuNPs carry antibodies for recognition of 
biomarkers. Second, numerous ECL signal-generating molecules of 
ABEI were immobilized on the surface of them for signal amplification. 
The biotinylated Ab1 immobilized on the surface of SA–AuNPs/1,3-
propanedithiol/Au, antigen cTnI, and ABEI–AuNPs–Ab2 nanoprobes 
fabricate a sandwich-type ECL immunosensor. The design and 
fabrication process are shown in Fig. 5. 
 
Fig.5. Schematic illustration of the fabrication process of the sandwich-type ECL 
immunosensor using SA–AuNPs as immobilization matrix and ABEI–AuNPs–Ab2 as 
probes.62 
According to Fig. 5, when the ABEI–AuNPs–Ab2 probes were 
reacted with Ag/BSA/bio-Ab1/SA–AuNPs/1,3-propanedithiol/Au 
substrate, strong ECL signals were obtained, and this is attributed to 
the ABEI–AuNPs–Ab2 molecules attached on the electrode surface and 
is the result of the reaction of ABEI radicals electro-oxidized by ABEI 
with hydrogen peroxide (H2O2) besides the catalysis of AuNPs. 
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In 2013, Li and coworkers indicated the possibility of a sensitive 
label-free ECL immunosensor employed by using luminol-
functionalized gold nanoparticles (luminol–AuNPs) as antibody carriers 
for detection of the cTnI acute biomarker.22 Luminol–AuNPs conjugated 
biotinylated antibodies against cTnI (biotin–anti-cTnI–luminol–AuNPs) 
were assembled onto a streptavidin-coated AuNPs (SA–AuNPs) 
modified electrode. 
Luminol molecules functionalized the surface of electrode for 
generating ECL signals, and they carried numerous biotin–anti-cTnI for 
connecting with the SA–AuNPs modified electrode and recognition of 
target cTnI. The fabrication process of the label-free ECL 
immunosensor using luminol–AuNPs is shown in Fig. 6. 
 
Fig.6. Schematic illustration of the fabrication processes of the label-free ECL 
immunosensor using luminol–AuNPs as antibody carriers and sensing platform.22 
The ECL reaction of luminol with H2O2 formed electrotransfer 
interactions. In the presence of AuNPs as the catalyst and the absence 
of cTnI, luminal anions and HO2− in alkaline solution were electro-
oxidized to L − and O2 − radicals. In the presence of cTnI, biotin–anti-
cTnI–luminol–AuNPs assembled Au electrode captured the target cTnI 
and an immune reaction happened. The ECL intensity is dependent on 
the concentration of cTnI.22 
SPR-based biosensor for cardiac troponin detection 
SPR immunosensing includes a thin metal film deposited on the 
surface of glass prism, and biorecognition elements containing 
proteins/antibodies/DNA/RNA have been immobilized on the surface of 
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the sensor.64 When antigen reacts with the biorecognition element, the 
refractive index as a variation in light intensity changes.65 
The surface plasmon resonance technique has been used for 
analytical application in immunosensors.66 The high sensitivity to the 
variation of mass on the transducer surface in this technique results 
from the refractive index alteration by immobilizing antibodies in 
immunosensors.48  
In 2007, Dutra and coworkers developed covalently immobilized 
antibody against cTnT on gold surface via a self-assembled monolayer 
(SAM) of thiols by using cysteamine coupling chemistry.67 
Immobilization methods are one of the most imperative aspects for the 
development of immunosensors. 
SAMs have shown some advantages such as high stability, 
acceptable orientation, and easy preparation, and they became a 
method to immobilize biological elements for biosensor development. 
Mercapto groups attached rigidly versatile SAM to the gold electrode 
surface.67 The amino groups of cysteamine SAM via cross-linking by 
glutaraldehyde immobilized antibodies on the surface of the sensor. A 
schematic of the SPR immunosensor for cTnT detection is shown in 
Fig. 7. 
 
Fig.7. Schematic representation of the principle of SPR immunosensor for cTnT 
determinations.67 
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In this study with SPR software (version 4.1.2 from Eco 
Chemie), the response of the SPR sensor was automatically monitored 
and antibodies were immobilized covalently via the use of SAMs, and 
they allowed repetitive measurement with cost savings.67 
In 2007, Dutra and Kubo proposed an SPR sensor in which 
streptavidin was immobilized on a replaceable carboxy methyl dextran 
hydrogel, which was used for binding biotinylated anti-troponin T 
monoclonal antibodies to detect human cardiac troponin T.68 The SPR 
sensor component involved a gold-coated glass disc covered covalently 
with carboxymethylated dextran. 
The dextran matrix, by the functionality of the surface, elevates 
the binding capacity of the surface that streptavidin ligand via amino 
groups is coupled to dextran. Biotinylated anti-troponin T monoclonal 
antibodies interacted with a streptavidin-coated sensor disc and were 
monitored by observing changes in the resonant angle.68 The 
interaction between biotinylated monoclonal antibodies for cTnT and 
streptavidin is shown in Fig. 8. 
 
Fig.8. Illustration of the immobilization scheme of biotinylated monoclonal antibody 
cTnT.68 
The nonspecific binding on the surface is one of the major 
problems in this method, and it can make changes in the resonant 
angle. There are several ways to minimize this problem such as 
washing after the antigen recognition by immobilized antibody and 
blocking free reactive sites by a selective layer.68 
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A linear range of detection was from 0.03 to 6.5 ng/ml. The 
system presented was possible to measure the cTnT without dilution of 
the human serum with good specificity and reproducibility.68 
In 2011, Liu and coworkers investigated immobilized troponin T 
antibody via SAM comprising a homogeneous mixture of oligo(ethylene 
glycol) (OEG)-terminated alkanethiolated and mercaptohexadecanoic 
acid (MHDA) on gold by using SPR. Oligo(ethylene glycol) resists the 
adsorption of protein from solution and has been employed for surface 
grafting. Because of high hydrophilicity, the hydrogen bond accepter, 
and the zero net charge, the SAM of OEG is suitable for making the 
antifouling surface. The functional group of the OEG cannot cross-link 
with biomolecules, and its antifouling ability is lost.69 
For this reason, OEG was combined with MHDA and created a 
mixed SAM. The MHDA has carboxyl groups that can be coupled with 
amine groups on the antibody through 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC)/N-
hydroxysulfosuccinimide (sulfo-NHS) using active sites.69 
Surface modification of the mixed SAM of OEG with MHDA and 
immobilization methods for binding antibody are shown in Fig. 9. 
 
Fig.9. Schematic diagram of surface modification for the mixed SAM of OEG and 
MHDA and the immobilization method of antibody binding carboxyl groups of MHDA on 
Au.69 
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The SPR biosensor detected troponin T within 2 min after 
injection in a linear detection range lower than 50 μg ml−1, and the 
limit of detection (LOD) of cardiac troponin T was 100 ng ml−1, which 
is not yet sufficient for clinical diagnostics.69 
Other optical-based biosensors for cardiac troponin 
detection 
One of the methods for troponin detection is based on an 
optomagnetic immunoassay technology. This method can be used in 
affinity-based assay for the detection of a broad range of biological 
molecules, including proteins, small molecules, and nucleic 
acid.70,71,72,73 
An optomagnetic biosensor based on nanoparticles that are 
magnetically actuated and optically detected in a sample fluid has 
been proposed for troponin detection.74,75 There are electromagnets 
placed above and below the cartridge that generate magnetic forces, 
and supermagnetic particles are controlled and accelerated by them.75 
In 2009, Bruls and coworkers coated the magnetic nanoparticles 
and the sensor surface with antibody, and magnetic nanoparticles 
were mixed into sample fluid in the cartridge.75 Due to the large total 
surface area of the dispersed nanoparticles, nanoparticles captured 
analyte molecules.76 Then, the electromagnets were applied to move 
the nanoparticles and localize them at the binding surface. For 
removing free and weakly bound particles from the surface, the 
magnetic field from the upper magnet is used. The optomagnetic 
system, with electromagnets and detection optics, was placed in the 
fluid microchamber.75 The design and assay process steps are shown 
in Fig. 10. 
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Fig.10. Optomagnetic immuno-biosensor based on actuated magnetic nanoparticles. 
(A) Schematic showing the assay process in the reaction microchamber: (1) antibody-
conjugated magnetic nanoparticles fill microchamber and capture analyte; (2) 
electromagnets generate magnetic field that is applied on magnetic particles to 
binding to the surface; (3) magnetic field from upper magnet is used to remove 
unbound and weakly bound particles. (B) Fluid microchamber placed in the 
optomagnetic system with electromagnets and detection optics. Light reflects from the 
sensor surface with an intensity that depends on the concentration of nanoparticles at 
the surface of the sensor, with the mechanism of frustrated total internal reflection (f-
TIR). 2D, two-dimensional. (C) Cartridge composed of two plastic parts connected by 
double-sided adhesive tape. The outer dimension of the cartridge is 1 × 4 cm. The 
cartridge includes a sample inlet, a channel, a reaction microchamber, and a vent. The 
volume of the reaction microchamber is 1 μl, and a total sample volume is 10 μl. (D) f-
TIR image of magnetic nanoparticles bound to the surface of the sensor through an 
immunoassay on 31 capture spots of 125 mm diameter each. (E) Schematic real-time 
curve of the measured optical signal for a single capture spot. The assay phases A(1) 
to A(3) are marked (see panel A). The signal modulation in phase A(2) is due to 
switched actuation of the magnetic nanoparticles.75 
For detecting the presence of magnetic nanoparticles on the 
binding surface, the optical principle of frustrated total internal 
reflection (f-TIR)77 was employed and is shown in Fig. 10B.75 
Bruls and coworkers developed a fast and sensitive cTnI test 
based on actuated magnetic nanoparticles. For this purpose, 
nanoparticles that were incubated with sample fluid were injected into 
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the cartridge. The actuation protocol was started, and magnetic force 
from the lower magnet was applied to particles. Particles carrying cTnI 
were concentrated at the surface, and cTnI was bound between 
antibody-coated nanoparticles and antibody-coated surface of the 
sensor. Then, the optical signal was changed.75 
Fluorescence resonance energy transfer (FRET) is known as a 
chemical transduction method that describes energy transfer between 
two light-sensitive molecules. Donor and acceptor molecules must be 
in close proximity. The absorption spectrum of the acceptor must 
overlap the fluorescence emission spectrum of the donor. The FRET 
biosensors are categorized into two types: intermolecular (or 
bimolecular) and intramolecular (or unimolecular).78 
In 2008, Stringer and coworkers employed biosensor-based 
FRET by using quantum dots as donors and organic dyes as acceptors 
for detection of troponin I.79 To detect the fluorescence, a liquid core 
waveguide was used that was able to achieve highly sensitive and 
accurate measurement. For this purpose, green quantum dot was used 
as the donor with an emission peak wavelength at approximately 
544 nm, and Invitrogen Alexa Fluor 546 (AF-546) fluorescent dye was 
used as acceptor, with the absorption peak wavelength directly 
overlapping with the emission peak wavelength of the donor. The 
amine-reactive ester on the surface of the quantum dot was created 
by using EDC and sulfo-NHS, and then protein A was labeled with 
carboxyl-functionalized quantum dot. Mouse anti-troponin I IgG 
monoclonal antibody was labeled with AF-546 fluorescent dye, and 
then the biosensor complex was fabricated. Antibodies include two FAB 
arms and a single FC stem, with FAB being bound to a single FC stem by 
means of a hinge region.80,81 Protein A is simultaneously able to bind 
two IgG antibodies via the FC portion of the IgG.82 Quantum dot-
labeled protein A and mouse anti-troponin I IgG monoclonal antibody-
labeled AF-546 fluorescent dye were incubated for 2 h at room 
temperature. After that, protein A binds to anti-troponin antibody and 
self-assembled optical biosensor is produced. A schematic of the self-
assembled optical biosensor architecture is shown in Fig. 11.79 
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Fig.11. Schematic of self-assembled optical biosensor architecture.79 
To obtain the emission spectrum with significant peak and large 
changes in energy transfer, the acceptor-to-donor ratio was given as 
4:1 AF-546 to quantum dot. When antibody captures antigen, 
conformational change occurs within the antibody structure. Due to 
changing distances between quantum dot as donor and AF-546 as 
acceptor, the energy transfer is altered.79 
Surface-enhanced Raman scattering (SERS) is a technique that 
offers orders of magnitude increases in Raman intensity, overcoming 
the traditional drawback of Raman scattering.83 SERS is of interest for 
trace material analysis, flow cytometry, and other applications where 
the current sensitivity/speed of a Raman measurement is insufficient. 
The enhancement occurs at a metal surface that has nanoscale 
roughness, and the molecules adsorbed onto that surface can undergo 
enhancement.83,84 Typical metals used are gold and silver. Preparation 
of the surface can be provided through electrochemical roughening, 
metallic coating of a nanostructured substrate, or deposition of 
metallic nanoparticles (often in a colloidal form). 
One of the more recently developed techniques for 
immunoassay and DNA detection is surface-enhanced Raman 
scattering.85 This technique is of high interest due to its high sensitivity 
and potential for multiplexing.62,86,87 Because Raman peaks are much 
narrower than fluorescence bands, SERS has potential for multiplex 
detection.88 SERS assay was used recently via SERS nano-tags and 
magnetic beads for a sandwich immunoassay.89,90 This method 
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includes two antibodies: one attached to the surface of magnetic 
beads and the other conjugated with a SERS nano-tag. As a result, the 
antigen is sandwiched between two antibodies.91 
In 2014, Chon and coworkers developed a SERS-based 
competitive immunoassay for detection of cTnI and CK-MB.91 For this 
reason, monoclonal antibodies for cTnI and CK-MB were immobilized 
onto the surface of magnetic beads, and two different types of SERS 
nano-tags were used for conjugated target antigen: cTnI and CK-MB. 
Samples including free target antigens and the antigens conjugated 
onto the surface, SERS nano-tags were injected into magnetic beads, 
and competitive reaction between the monoclonal antibodies on the 
magnetic beads and free target antigens and the antigens conjugated 
on the surface of SERS nano-tags started. By using a small magnetic 
bar, the immunocomplexes were separated and the Raman signals of 
the remaining SERS nano-tags in supernatant were examined. In this 
study, two type of SERS nano-tags were used. Malachite green 
isothiocyanate (MGITC) and X-rhodamine-5(and 6)-isothiocyanate 
(XRITC) were used as Raman reporter molecules. Hallow gold 
nanospheres (HGNs) have been used for conjugating cTnI and CK-MB 
antigens.91 
Conclusions and perspectives 
The importance of cardiac troponin biomarkers for the 
fabrication of immunosensors and their application in acute myocardial 
infarction concept are known. Fabrication and modification of 
immunosensors by the incorporation of biological molecules via 
different methods have been carried out to improve the detection of 
specified biomarkers. 
Recent advances in the optical immunosensing of cardiac 
troponin biomarkers was summarized, and the conception of detection 
and development of devices based on optical detection principles was 
considered and implies that for fabrication of an ideal diagnosis of 
cardiovascular diseases at early stages, it is essential to detect cardiac 
troponin biomarkers with a simple and sensitive method at very low 
levels of troponin through optical measurement in various methods 
such as colorimetric, fluorescence, luminescence, and surface plasmon 
resonance. Several disadvantages of optical immunosensors, such as 
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bulkiness, high cost, and difficult labeling procedures, were described. 
Thus, clinical biosensors based on the colorimetric method using 
PDMS–AuNPs composite film with silver enhancement have been 
successfully attempted for cTnI detection in less than 20 min and a 
limit of detection of 0.01 ng/ml. Furthermore, the advantages of the 
colorimetric method have been considered in the ease of fabrication 
and operation and low cost, whereas in SPR immunosensors the 
detection of cTnI in a linear range from 0.03 to 6.5 ng/ml has been 
reported. In addition, the detection limit of the mentioned sensors was 
0.01 ng/ml with the merits of good repeatability and specificity and 
concurrently compared to the fabrication strategy of the biosensor 
based on ECL immunosensors for the detection of cTnI. Moreover, ECL 
immunosensors, by using luminal–AuNPs as antibody with a wide 
range from 0.1 to 1000 ng/ml and a limit of detection of 0.06 ng/ml, 
have shown great application potential in clinical and pharmaceutical 
analysis, and the optomagnetic biosensor technology based on 
actuated nanoparticles for troponin detection has proposed advantages 
such as high-sensitivity, rapid multiplexed assays on a small sample 
volume and low-cost disposable cartridge. 
Finally, the precision of troponin assay improvement will be 
continued and will ameliorate earlier diagnosis of acute myocardial 
infarction and better risk stratification on the use of the new highly 
sensitive assays. It is worth mentioning that testing for troponin has 
not been set at the same level of precision as highly automated 
methods and still remains as an area for deeper understanding and 
efficacy evaluations, and we reported that the optical biosensors with 
highly specific detection of troponin have the ability for more 
investigation in clinical applications. 
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